Venetoclax regimen not superior to standard therapy alone for older patients with CLL
Tailored Treatment Strategies for Chronic Lymphocytic Leukemia in a Rapidly Changing Era | American Society of Clinical Oncology Educational Book
Ibrutinib in Combination with Rituximab or Lenalidomide/Rituximab for Untreated FL | Research To Practice
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study | Leukemia
FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL | Clinical Hematology International
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study | Leukemia
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia - ScienceDirect
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial - The Lancet Oncology
Treatment Initiation and Selection in Newly Diagnosed CLL - ppt download
Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia | Annals of Hematology
Studies on ibrutinib for newly diagnosed chronic lymphocytic leukemia... | Download Scientific Diagram
Management of CLL in 2021 and Beyond - YouTube
Ibrutinib in B-cell lymphoma: single fighter might be enough? | Cancer Cell International | Full Text
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy - Oncology Nurse Advisor
CHRONIC LYMPHOCYTIC LEUKEMIA
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia | NEJM
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
Ibrutinib combinations in CLL therapy: scientific rationale and clinical results | Blood Cancer Journal
Ongoing or planned phase 3 trials in the first-line setting for CLL | Download Table
British Journal of Haematology | Wiley Online Library
ALLIANCE - Progression-Free Survival | IMBRUVICA® (ibrutinib) HCP
A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma | Haematologica
Cancers | Free Full-Text | First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era
Ibrutinib (PCI-32765) | Btk Inhibitor | MedChemExpress
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL | NEJM
